Horizon Pharma Inc (HZNP) 14.83 $HZNP
Horizon Pharma plc Provides Update on Relationship With Specialty Pharmacies
Marketwired - Wed Oct 21, 4:55PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today provided an update on its relationship with specialty pharmacies:
HZNP: 14.83 (-0.43)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Horizon Pharma plc - HZNP
ACCESSWIRE - Wed Oct 21, 4:46PM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Horizon Pharma plc ("Horizon" or the "Company"
(NASDAQ: HZNP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
HZNP: 14.83 (-0.43)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Horizon Pharma plc And Encourages Investors To Contact The Firm
Business Wire - Wed Oct 21, 2:40PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Horizon Pharma plc ("Horizon" or the "Company" (NASDAQ: HZNP). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
HZNP: 14.83 (-0.43)
Horizon Pharmaceutical (HZNP) Stock Tumbles on Use of Specialty Pharmacies
at The Street - Wed Oct 21, 1:27PM CDT
Horizon Pharmaceutical (HZNP) stock is declining in afternoon trading, as it and Valeant Pharmaceuticals are scrutinized for their use of specialty pharmacies.
HZNP: 14.83 (-0.43)
INVESTIGATION ALERT: Rigrodsky & Long, P.A. Announces Commencement of an Investigation of Horizon Pharma plc for Possible Violations of Federal Securities Laws
PR Newswire - Wed Oct 21, 1:06PM CDT
Rigrodsky & Long, P.A.:
HZNP: 14.83 (-0.43)
Targets of Market Hatred Can Change Daily
at The Street - Wed Oct 21, 12:03PM CDT
It used to be industrials, now it's health care.
TSLA: 210.09 (-2.94), VRX: 118.61 (-28.13), GE: 28.85 (+0.07), CLX: 122.06 (-0.02), VMW: 55.42 (-13.34), NKE: 132.47 (+0.10), HON: 98.77 (+0.49), UTX: 97.97 (+2.35), WMT: 58.64 (-0.11), INTC: 33.37 (-0.07), SLB: 75.63 (+0.08), K: 69.61 (+0.64), SBUX: 60.53 (-0.35), CMG: 665.67 (-39.96), HZNP: 14.83 (-0.43), COST: 155.21 (+0.65), EMC: 25.77 (-1.72), CRZO: 38.09 (-1.55), PPG: 100.64 (-0.74), BHI: 54.41 (+1.24), ETN: 52.52 (+0.15), SWKS: 77.67 (-0.62), HAL: 38.40 (+0.72), HRL: 66.61 (+0.67), NXPI: 91.32 (-0.67), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), NFLX: 97.96 (-1.03), LB: 96.52 (+0.14), LRCX: 70.79 (+0.76), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), DOV: 61.88 (+0.35), KLAC: 63.98 (+10.12), AVGO: 120.50 (+0.61), SNDK: 76.78 (+1.59)
Horizon Pharma plc Announces Favorable Markman Ruling in RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid Patent Infringement Lawsuit
Marketwired - Wed Oct 21, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that a favorable Markman ruling has been issued by Judge Roy Payne in the United States District Court for the Eastern District of Texas Marshall Division in the patent infringement lawsuit filed by Horizon against Par Pharmaceutical, Inc. for an Abbreviated New Drug Application ("ANDA" to market a generic version of RAVICTI.
HZNP: 14.83 (-0.43)
HZNP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Horizon Pharma plc and Certain Officers and Directors
Business Wire - Tue Oct 20, 3:39PM CDT
Levi & Korsinsky, LLP announces that it has commenced an investigation of Horizon Pharma plc ("Horizon Pharma" or the "Company" (NASDAQGS:HZNP) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
HZNP: 14.83 (-0.43)
Jim Cramer -- Microsoft, IBM Should Have Their Eyes on the Buys
at The Street - Tue Oct 20, 1:20PM CDT
If you ask Jim Cramer (and social media users did), Microsoft should acquire Salesforce, IBM should grab Box, pharmaceuticals have a political problem, and there's no substitute for Berkshire Hathaway.
WFM: 32.98 (-0.24), VRX: 118.61 (-28.13), BOX: 12.64 (-0.79), TREE: 94.49 (-4.25), TFM: 26.64 (-0.96), PSTG: 19.25 (-0.25), WFC: 53.12 (+0.04), MKL: 850.00 (-7.57), WWAV: 40.37 (+0.12), RDUS: 61.45 (-3.93), LEN: 52.09 (+0.27), IBM: 140.92 (+0.28), HZNP: 14.83 (-0.43), WY: 29.22 (+0.08), MSFT: 47.20 (-0.57), TOL: 36.58 (-0.25), BRK.A: 199,900.00 (-1,580.00), CRM: 75.83 (-1.70)
Horizon Pharma plc to Host Third Quarter 2015 Conference Call and Webcast on November 6, 2015
Marketwired - Fri Oct 16, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its third quarter 2015 financial results will be released on Friday, November 6, 2015. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
HZNP: 14.83 (-0.43)
Horizon Pharma plc Files Definitive Proxy Statement for Extraordinary General Meeting of Horizon Pharma Shareholders
Marketwired - Thu Oct 15, 6:01AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma" , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has filed a definitive proxy statement on Schedule 14A with the Securities and Exchange Commission ("SEC" in connection with the extraordinary general meeting of Horizon Pharma shareholders (the "Meeting" . The principal purpose of the Meeting is to approve the issuance of Horizon ordinary shares in connection with Horizon Pharma's proposed acquisition of Depomed, Inc.
HZNP: 14.83 (-0.43), DEPO: 16.12 (-0.95)
Three Canadian Biotechs with Pending Catalysts
ACCESSWIRE - Wed Oct 14, 11:02AM CDT
CORAL GABLES, FL / ACCESSWIRE / October 14, 2015 / In the rush of sector-wide biotech news, especially since Hillary Clinton's now infamous tweet that rocked the entire sector late last month, some developments that would have otherwise been big news may have gotten a bit lost in the ruckus. This is even more the case with foreign stocks that already receive less focus than US-based biotechs. Lest we lose sight of potential opportunities, here are three Canadian biotechs with catalysts pending.
HZNP: 14.83 (-0.43), TRIL: 13.31 (-0.43)
Horizon Pharma plc Files Preliminary Proxy Materials for Special Meetings
Marketwired - Tue Oct 13, 3:30PM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma" , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has filed preliminary proxy materials on Schedule 14A with the Securities and Exchange Commission ("SEC" in connection with its solicitation of proxies to vote in favor of proposals at two related special meetings of Depomed, Inc. ("Depomed" that Horizon Pharma is currently soliciting consents from Depomed shareholders to call one special meeting to remove all of the current Depomed directors and repeal a series of recent amendments to Depomed's bylaws (the "Removal and Bylaw Amendments Special Meeting" and a second special meeting to elect replacement directors (the "Election Special Meeting" .
HZNP: 14.83 (-0.43), DEPO: 16.12 (-0.95)
Timothy P. Walbert Joins Sucampo's Board of Directors
GlobeNewswire - Tue Oct 13, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that Timothy P. Walbert has joined Sucampo's Board of Directors. Mr. Walbert currently serves as Chairman, President and Chief Executive Officer of Horizon Pharma plc.
SCMP: 17.23 (-0.45), HZNP: 14.83 (-0.43)
Alcoa and Gap are big market movers
AP - Fri Oct 09, 3:26PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
HELE: 98.49 (-2.08), AA: 9.11 (-0.30), HZNP: 14.83 (-0.43), ASNA: 12.95 (-0.32), GPS: 26.98 (-0.17), APOL: 10.60 (-0.26)
Horizon passes regulatory hurdle in pursuit of Depomed
AP - Fri Oct 09, 7:09AM CDT
NEW YORK (AP) — Horizon Pharma cleared one hurdle in its hostile bid for Depomed.
HZNP: 14.83 (-0.43), DEPO: 16.12 (-0.95)
Horizon Pharma plc Chairman and Chief Executive Officer Timothy P. Walbert Inducted Into Chicago Area Entrepreneurship Hall of Fame at UIC Institute for Entrepreneurial Studies
Marketwired - Fri Oct 09, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Chairman, President and Chief Executive Officer Timothy P. Walbert, received the Chicago Area Entrepreneurship Hall of Fame Award from the University of Illinois at Chicago's (UIC) Institute for Entrepreneurial Studies (IES). The award recognizes distinguished business people who have demonstrated their entrepreneurial talent by fostering a thriving, diversified economic engine in Chicago and have enhanced Chicago's communities.
EGLT: 9.13 (-1.15), HZNP: 14.83 (-0.43)
Telesta Therapeutics Appoints Brian J. Groch as Chief Commercial Officer
CNW Group - Thu Oct 08, 6:00AM CDT
Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced the engagement of Brian J. Groch as Chief Commercial Officer, a new executive position reflecting the company's strategic transformation to a U.S. focused specialty pharmaceutical company. As Chief Commercial Officer, Brian will be responsible for leading the development and execution of Telesta's commercial strategy beginning with the U.S. commercial launch of MCNA(1) for 2(nd) line high risk non-muscle invasive bladder cancer, following its potential U.S. marketing approval in Q1/2016.
TST.TO: 0.41 (+0.02), HZNP: 14.83 (-0.43)
Horizon Pharma plc Announces That Three of the Leading Proxy Advisory Firms Recommend That Depomed Shareholders Provide Consent FOR the Special Meetings Requests
Marketwired - Wed Oct 07, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma" , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Proxy Mosaic's ("Proxy Mosaic" recommendation in support of Horizon Pharma's efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. ("Depomed" directors and to repeal a series of recent amendments to Depomed's bylaws.
HZNP: 14.83 (-0.43), DEPO: 16.12 (-0.95)
Horizon Pharma plc Provides Update on Relationship With Specialty Pharmacies
Marketwired - Wed Oct 21, 4:55PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today provided an update on its relationship with specialty pharmacies:
HZNP: 14.83 (-0.43)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Horizon Pharma plc - HZNP
ACCESSWIRE - Wed Oct 21, 4:46PM CDT
NEW YORK, NY / ACCESSWIRE / October 21, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Horizon Pharma plc ("Horizon" or the "Company"
(NASDAQ: HZNP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. HZNP: 14.83 (-0.43)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Horizon Pharma plc And Encourages Investors To Contact The Firm
Business Wire - Wed Oct 21, 2:40PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Horizon Pharma plc ("Horizon" or the "Company"
(NASDAQ: HZNP). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. HZNP: 14.83 (-0.43)
Horizon Pharmaceutical (HZNP) Stock Tumbles on Use of Specialty Pharmacies
at The Street - Wed Oct 21, 1:27PM CDT
Horizon Pharmaceutical (HZNP) stock is declining in afternoon trading, as it and Valeant Pharmaceuticals are scrutinized for their use of specialty pharmacies.
HZNP: 14.83 (-0.43)
INVESTIGATION ALERT: Rigrodsky & Long, P.A. Announces Commencement of an Investigation of Horizon Pharma plc for Possible Violations of Federal Securities Laws
PR Newswire - Wed Oct 21, 1:06PM CDT
Rigrodsky & Long, P.A.:
HZNP: 14.83 (-0.43)
Targets of Market Hatred Can Change Daily
at The Street - Wed Oct 21, 12:03PM CDT
It used to be industrials, now it's health care.
TSLA: 210.09 (-2.94), VRX: 118.61 (-28.13), GE: 28.85 (+0.07), CLX: 122.06 (-0.02), VMW: 55.42 (-13.34), NKE: 132.47 (+0.10), HON: 98.77 (+0.49), UTX: 97.97 (+2.35), WMT: 58.64 (-0.11), INTC: 33.37 (-0.07), SLB: 75.63 (+0.08), K: 69.61 (+0.64), SBUX: 60.53 (-0.35), CMG: 665.67 (-39.96), HZNP: 14.83 (-0.43), COST: 155.21 (+0.65), EMC: 25.77 (-1.72), CRZO: 38.09 (-1.55), PPG: 100.64 (-0.74), BHI: 54.41 (+1.24), ETN: 52.52 (+0.15), SWKS: 77.67 (-0.62), HAL: 38.40 (+0.72), HRL: 66.61 (+0.67), NXPI: 91.32 (-0.67), BA: 141.19 (+2.31), WDC: 71.44 (-3.42), NFLX: 97.96 (-1.03), LB: 96.52 (+0.14), LRCX: 70.79 (+0.76), GM: 35.42 (+1.94), MCD: 102.54 (-1.30), DOV: 61.88 (+0.35), KLAC: 63.98 (+10.12), AVGO: 120.50 (+0.61), SNDK: 76.78 (+1.59)
Horizon Pharma plc Announces Favorable Markman Ruling in RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid Patent Infringement Lawsuit
Marketwired - Wed Oct 21, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that a favorable Markman ruling has been issued by Judge Roy Payne in the United States District Court for the Eastern District of Texas Marshall Division in the patent infringement lawsuit filed by Horizon against Par Pharmaceutical, Inc. for an Abbreviated New Drug Application ("ANDA"
to market a generic version of RAVICTI. HZNP: 14.83 (-0.43)
HZNP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Horizon Pharma plc and Certain Officers and Directors
Business Wire - Tue Oct 20, 3:39PM CDT
Levi & Korsinsky, LLP announces that it has commenced an investigation of Horizon Pharma plc ("Horizon Pharma" or the "Company"
(NASDAQGS:HZNP) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. HZNP: 14.83 (-0.43)
Jim Cramer -- Microsoft, IBM Should Have Their Eyes on the Buys
at The Street - Tue Oct 20, 1:20PM CDT
If you ask Jim Cramer (and social media users did), Microsoft should acquire Salesforce, IBM should grab Box, pharmaceuticals have a political problem, and there's no substitute for Berkshire Hathaway.
WFM: 32.98 (-0.24), VRX: 118.61 (-28.13), BOX: 12.64 (-0.79), TREE: 94.49 (-4.25), TFM: 26.64 (-0.96), PSTG: 19.25 (-0.25), WFC: 53.12 (+0.04), MKL: 850.00 (-7.57), WWAV: 40.37 (+0.12), RDUS: 61.45 (-3.93), LEN: 52.09 (+0.27), IBM: 140.92 (+0.28), HZNP: 14.83 (-0.43), WY: 29.22 (+0.08), MSFT: 47.20 (-0.57), TOL: 36.58 (-0.25), BRK.A: 199,900.00 (-1,580.00), CRM: 75.83 (-1.70)
Horizon Pharma plc to Host Third Quarter 2015 Conference Call and Webcast on November 6, 2015
Marketwired - Fri Oct 16, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that its third quarter 2015 financial results will be released on Friday, November 6, 2015. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
HZNP: 14.83 (-0.43)
Horizon Pharma plc Files Definitive Proxy Statement for Extraordinary General Meeting of Horizon Pharma Shareholders
Marketwired - Thu Oct 15, 6:01AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"
, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has filed a definitive proxy statement on Schedule 14A with the Securities and Exchange Commission ("SEC" in connection with the extraordinary general meeting of Horizon Pharma shareholders (the "Meeting" . The principal purpose of the Meeting is to approve the issuance of Horizon ordinary shares in connection with Horizon Pharma's proposed acquisition of Depomed, Inc. HZNP: 14.83 (-0.43), DEPO: 16.12 (-0.95)
Three Canadian Biotechs with Pending Catalysts
ACCESSWIRE - Wed Oct 14, 11:02AM CDT
CORAL GABLES, FL / ACCESSWIRE / October 14, 2015 / In the rush of sector-wide biotech news, especially since Hillary Clinton's now infamous tweet that rocked the entire sector late last month, some developments that would have otherwise been big news may have gotten a bit lost in the ruckus. This is even more the case with foreign stocks that already receive less focus than US-based biotechs. Lest we lose sight of potential opportunities, here are three Canadian biotechs with catalysts pending.
HZNP: 14.83 (-0.43), TRIL: 13.31 (-0.43)
Horizon Pharma plc Files Preliminary Proxy Materials for Special Meetings
Marketwired - Tue Oct 13, 3:30PM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"
, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has filed preliminary proxy materials on Schedule 14A with the Securities and Exchange Commission ("SEC" in connection with its solicitation of proxies to vote in favor of proposals at two related special meetings of Depomed, Inc. ("Depomed" that Horizon Pharma is currently soliciting consents from Depomed shareholders to call one special meeting to remove all of the current Depomed directors and repeal a series of recent amendments to Depomed's bylaws (the "Removal and Bylaw Amendments Special Meeting" and a second special meeting to elect replacement directors (the "Election Special Meeting" . HZNP: 14.83 (-0.43), DEPO: 16.12 (-0.95)
Timothy P. Walbert Joins Sucampo's Board of Directors
GlobeNewswire - Tue Oct 13, 5:45AM CDT
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that Timothy P. Walbert has joined Sucampo's Board of Directors. Mr. Walbert currently serves as Chairman, President and Chief Executive Officer of Horizon Pharma plc.
SCMP: 17.23 (-0.45), HZNP: 14.83 (-0.43)
Alcoa and Gap are big market movers
AP - Fri Oct 09, 3:26PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
HELE: 98.49 (-2.08), AA: 9.11 (-0.30), HZNP: 14.83 (-0.43), ASNA: 12.95 (-0.32), GPS: 26.98 (-0.17), APOL: 10.60 (-0.26)
Horizon passes regulatory hurdle in pursuit of Depomed
AP - Fri Oct 09, 7:09AM CDT
NEW YORK (AP) — Horizon Pharma cleared one hurdle in its hostile bid for Depomed.
HZNP: 14.83 (-0.43), DEPO: 16.12 (-0.95)
Horizon Pharma plc Chairman and Chief Executive Officer Timothy P. Walbert Inducted Into Chicago Area Entrepreneurship Hall of Fame at UIC Institute for Entrepreneurial Studies
Marketwired - Fri Oct 09, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Chairman, President and Chief Executive Officer Timothy P. Walbert, received the Chicago Area Entrepreneurship Hall of Fame Award from the University of Illinois at Chicago's (UIC) Institute for Entrepreneurial Studies (IES). The award recognizes distinguished business people who have demonstrated their entrepreneurial talent by fostering a thriving, diversified economic engine in Chicago and have enhanced Chicago's communities.
EGLT: 9.13 (-1.15), HZNP: 14.83 (-0.43)
Telesta Therapeutics Appoints Brian J. Groch as Chief Commercial Officer
CNW Group - Thu Oct 08, 6:00AM CDT
Telesta Therapeutics Inc. (TSX: TST) (PNK: BNHLF) today announced the engagement of Brian J. Groch as Chief Commercial Officer, a new executive position reflecting the company's strategic transformation to a U.S. focused specialty pharmaceutical company. As Chief Commercial Officer, Brian will be responsible for leading the development and execution of Telesta's commercial strategy beginning with the U.S. commercial launch of MCNA(1) for 2(nd) line high risk non-muscle invasive bladder cancer, following its potential U.S. marketing approval in Q1/2016.
TST.TO: 0.41 (+0.02), HZNP: 14.83 (-0.43)
Horizon Pharma plc Announces That Three of the Leading Proxy Advisory Firms Recommend That Depomed Shareholders Provide Consent FOR the Special Meetings Requests
Marketwired - Wed Oct 07, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"
, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Proxy Mosaic's ("Proxy Mosaic" recommendation in support of Horizon Pharma's efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. ("Depomed" directors and to repeal a series of recent amendments to Depomed's bylaws. HZNP: 14.83 (-0.43), DEPO: 16.12 (-0.95)
